Head to Head Survey: Smith & Nephew SNATS (SNN) & Uroplasty (UPI)
Smith & Nephew SNATS (NYSE: SNN) and Uroplasty (NYSE:UPI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Valuation & Earnings
This table compares Smith & Nephew SNATS and Uroplasty’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Smith & Nephew SNATS||$4.68 billion||3.60||$1.32 billion||N/A||N/A|
Smith & Nephew SNATS has higher revenue and earnings than Uroplasty.
Smith & Nephew SNATS pays an annual dividend of $0.61 per share and has a dividend yield of 1.6%. Uroplasty does not pay a dividend. Uroplasty has raised its dividend for 4 consecutive years.
This table compares Smith & Nephew SNATS and Uroplasty’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew SNATS||N/A||N/A||N/A|
Institutional & Insider Ownership
6.4% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Smith & Nephew SNATS and Uroplasty, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew SNATS||0||4||3||0||2.43|
Smith & Nephew SNATS currently has a consensus target price of $42.00, indicating a potential upside of 9.09%. Given Smith & Nephew SNATS’s higher possible upside, equities research analysts plainly believe Smith & Nephew SNATS is more favorable than Uroplasty.
Smith & Nephew SNATS beats Uroplasty on 9 of the 10 factors compared between the two stocks.
Smith & Nephew SNATS Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Uroplasty Company Profile
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Stock Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related stocks with our FREE daily email newsletter.